Myopic Macular Degeneration Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Myopic Macular Degeneration Epidemiology Forecast Report Coverage

Expert Market Research's “Myopic Macular Degeneration Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of myopic macular degeneration. It projects the future incidence and prevalence rates of myopic macular degeneration cases across various populations. The study covers age, gender, and type as major determinants of the myopic macular degeneration population. The report highlights patterns in the prevalence of myopic macular degeneration over time and projects future trends based on multiple variables.

Myopic Macular Degeneration Understanding: Disease Overview

Myopic macular degeneration is a vision-threatening complication of high myopia, characterized by progressive degenerative changes in the macula. It includes atrophic lesions, chorioretinal thinning, lacquer cracks, and myopic choroidal neovascularization. Aging populations and rising global myopia rates have driven increasing incidence, especially in East Asia. MMD can lead to irreversible central vision loss and substantial functional impairment. Classification systems such as META-PM assist in grading disease severity. Limited regenerative options underscore the need for earlier detection, risk stratification, and long-term monitoring in high-risk individuals.

Myopic Macular Degeneration Epidemiology Perspective

The myopic macular degeneration epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the myopic macular degeneration epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for myopic macular degeneration and their trends. The myopic macular degeneration detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Approximately 1.7% of the general population is affected by myopic macular degeneration, with estimates ranging 1.1 to 2.6%, highlighting its growing ocular health burden.
• The prevalence of high myopia, the principal risk factor for MMD, has risen sharply over recent decades. In 2010, approximately 163 million people (2.7% of the global population) had high myopia. By 2050, projections suggest that nearly 1 billion people (9.8%) will be affected.
• Among those with high myopia, 10–40% eventually develop pathologic changes in the macula consistent with MMD. This translates to a global prevalence of MMD between 1–3% at present, expected to reach 5–10% by mid-century.
• Myopic macular degeneration (MMD) affects approximately 1.7% of the global population, rising to ≈49% among individuals with high myopia, with a higher risk in older adults, women, and Asians.
• Prevalence of MMD rises with age, starting in 50–59 years, increasing in 60-69 years, and peaking in those 70+, especially among high myopia patients. Females are at higher risk than males, likely due to sex-specific differences in ocular anatomy and disease susceptibility.

Read more about this report - Request a Free Sample

Country-wise Myopic Macular Degeneration Epidemiology Segment

The myopic macular degeneration epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

East Asia (China, Japan, Korea, Singapore, Taiwan) bears the highest prevalence of both high myopia and MMD. Studies show that up to 80–90% of young adults are myopic, and 1–4% of the total population show pathologic myopic changes. In Japan, MMD is the leading cause of blindness, accounting for up to 30% of legal blindness cases.

In Europe and North America, the prevalence of high myopia has risen to 20–30% in adults, and MMD affects approximately 1–2% of the population. Although lower than in East Asia, the trend is upward, especially among younger generations engaged in prolonged near work and digital screen exposure.

Myopic Macular Degeneration: Treatment Overview

Treatment of myopic macular degeneration depends on disease subtype. Myopic choroidal neovascularization is primarily managed using intravitreal anti-VEGF injections, which offer effective vision stabilization. Atrophic MMD lacks curative therapy, requiring supportive approaches such as low-vision rehabilitation and optical aids. Preventive strategies focus on controlling high myopia progression, particularly in younger populations. Ongoing research explores scleral reinforcement, regenerative therapies, and long-acting biologics. Improved imaging and monitoring tools are enhancing early detection and personalized treatment pathways, supporting better long-term visual outcomes for individuals at risk of MMD progression.

Key Questions Answered

• What are the key findings of myopic macular degeneration epidemiology in the 8 major markets?
• What will be the total number of patients with myopic macular degeneration across the 8 major markets during the forecast period?
• What was the country-wise myopic macular degeneration epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of myopic macular degeneration during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of myopic macular degeneration during the forecast period of 2026-2035?
• What are the currently available treatments for myopic macular degeneration?
• What are the disease risks, signs, symptoms, and unmet needs of myopic macular degeneration?

Scope of the Myopic Macular Degeneration Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of myopic macular degeneration based on several factors.
• Myopic Macular Degeneration Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The myopic macular degeneration report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Age-Related Macular Degeneration Market

Macular Degeneration Drug Pipeline Analysis